- Report
- March 2024
- 188 Pages
Global
From €3244EUR$3,374USD£2,783GBP
€3605EUR$3,749USD£3,092GBP
- Report
- May 2024
- 372 Pages
Global
From €5240EUR$5,450USD£4,496GBP
- Report
- November 2023
- 146 Pages
Global
From €2403EUR$2,499USD£2,061GBP
- Report
- October 2023
- 150 Pages
Global
From €4663EUR$4,850USD£4,001GBP
- Report
- May 2024
- 546 Pages
Global
From €6726EUR$6,995USD£5,770GBP
- Report
- May 2024
- 541 Pages
Global
From €6726EUR$6,995USD£5,770GBP
- Report
- August 2023
- 1500 Pages
Global
From €8414EUR$8,750USD£7,218GBP
- Report
- October 2023
- 253 Pages
Global
From €4760EUR$4,950USD£4,083GBP
- Report
- March 2024
- 192 Pages
Global
From €3244EUR$3,374USD£2,783GBP
€3605EUR$3,749USD£3,092GBP
- Report
- May 2024
- 158 Pages
Global
From €5240EUR$5,450USD£4,496GBP
- Report
- January 2024
- 200 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- December 2023
- 200 Pages
Global
From €3846EUR$4,000USD£3,299GBP
- Report
- January 2024
- 182 Pages
Global
From €4712EUR$4,900USD£4,042GBP
- Report
- June 2023
- 115 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Report
- January 2024
- 200 Pages
Global
From €3990EUR$4,150USD£3,423GBP
- Report
- September 2021
- 144 Pages
China
From €3846EUR$4,000USD£3,299GBP
- Report
- July 2020
- 300 Pages
Global
From €5288EUR$5,500USD£4,537GBP
- Report
- February 2024
- 72 Pages
South Korea
From €4808EUR$5,000USD£4,124GBP
- Report
- January 2023
- 195 Pages
Latin America
From €4808EUR$5,000USD£4,124GBP
- Report
- June 2022
- 55 Pages
India
From €4808EUR$5,000USD£4,124GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more